Gene Mack - Apr 8, 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Financial Officer
Signature
/s/ Daniel C. Porco, Attorney-in-Fact
Stock symbol
GANX
Transactions as of
Apr 8, 2024
Transactions value $
$0
Form type
4
Date filed
4/8/2024, 07:44 PM
Previous filing
Apr 8, 2024
Next filing
Aug 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +200K $0.00 200K Apr 8, 2024 Common Stock 200K $3.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on April 8, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.